Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung05: T-DXd in HER2-mutant Metastatic NSCLC
NCT05246514Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate (ICR-assessed) up to 28 months. Started Jul 2022; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05246514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246514.